Ten years of diphtheria toxin testing and toxigenic cutaneous diphtheria investigations in Alberta, Canada: a highly-vaccinated population
Abstract Respiratory diphtheria is a potentially-fatal toxin-mediated disease that is rare among highly-vaccinated populations. Cutaneous infections with toxigenic Corynebacterium diphtheriae are most commonly linked to travel to an endemic region, though C. ulcerans has emerged as a predominant, locally-acquired cause of respiratory and cutaneous diphtheria in Western Europe. Recently, public health agencies from several highly-vaccinated regions expanded their guidelines to investigate toxigenic cutaneous diphtheria regardless of travel history. With relatively unknown epidemiology of C. diphtheriae in North America, and increasing diphtheria toxin testing over the last decade, this change could lead to substantial increases in public health investigations with unclear benefits. Therefore, this study examined the diagnostic and public health benefits of toxigenic cutaneous diphtheria investigations in the highly-vaccinated population of Alberta, Canada, where travel history is not required for cutaneous diphtheria investigations. Reviewing all C. diphtheriae isolates collected between 2010–2019, 82% were isolated from cutaneous sites and 5% were toxigenic. Three cases of toxigenic cutaneous disease were identified, none from patients with recent travel. Contact tracing identified asymptomatic C. diphtheriae colonization among 0–26% of close contacts, with identical isolate profiles among colonized contacts and primary cases. Overall, this study supports the exclusion of travel history as a prerequisite for public health investigations in North America. While further studies are needed to assess the prevalence and impact of endemic C. ulcerans in North America, this study suggests differing epidemiology of toxigenic corynebacteria compared to Europe and underscores the importance of including C. ulcerans in changing public health guidelines.